Pharmacist intervention in risk reduction study: High-risk cardiac patients

Canadian Pharmacists Journal

Volumn 140, Issue 1, 2007, Pages 32-37

  Semchuk, William ^a   Taylor, Jeffrey ^b   Sulz, L ^a   Deschamps, M ^c   Tsuyuki, Ross T ^d   Duffy, P ^a   Wilson, T ^b  

^a REGINA QU APPELLE HEALTH REGION   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c CFB Gagetown   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PHARMACIST; PHYSICIAN; PROFESSIONAL PRACTICE; REVIEW; RISK REDUCTION; TRAINING;

EID: 33846361830     PISSN: 17151635     EISSN: None     Source Type: Journal    
DOI: 10.1177/171516350714000123     Document Type: Review

References (18)

1. Heart and Stroke Foundation of Canada. The growing burden of heart disease and stroke in Canada 2003. Ottawa, ON; 2003.
2. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: 2003 update. CMAJ 2003;168(9):921-4.
3. Khan N, McAlister F, Lewanczuk R, et al. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol 2005;21(8):657-77.
4. Canadian Diabetes Association Practice Guideline Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and treatment of diabetes in Canada. Can J Diabetes 2003;27(Suppl 2):S1-S141.
5. Joffres MR, Ghadirian P, Fodor JG, et al. Awareness, treatment and control of hypertension in Canada. Am J Hypertens 1997;10:1097-102.
6. Pearson T, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP). Arch Intern Med 2000;160:459-67.
7. Bourgault C, Davignon J, Fodor G, et al. Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study - Observational (CALIPSO). Can J Cardiol 2005;21(13):1187-93.
8. Harris S, Ekoe JM, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting (results of the Diabetes in Canada Evaluation study). Diabetes Res Clin Pract 2005;70(1):90-7.
9. Erickson SR, Slaughter R, Halapy H. Pharmacists' ability to influence outcomes of hypertension therapy. Pharmacotherapy 1997;17(1):140-7.
10. Bogden PE, Abbott RD, Williamson P, et al. Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension. J Gen Intern Med 1998;13:740-5.
11. Bogden PE, Koontz LM, Williamson P, et al. The physician and pharmacist team. J Gen Intern Med 1998;13:158-64.
12. Bozovich M, Rubino EM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving national cholesterol education program low-density lipoprotein goals. Pharmocotherapy 2000;20:1375-83.
13. Ellis SL, Carter BL, Malone DE, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older patients: the IMPROVE study. Pharmacotherapy 2000;20:1508-16.
14. Irons BK, Lenz RJ, Anderson SL, et al. A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy 2002;22:1294-1300.
15. Jaber LA, Halapy H, Fernet M, et al. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 1996;30:238-43.
16. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002;162:1149-55.
17. Geber J, Parra D, Beckey N, Korman L. Optimizing drug therapy in patients with cardiovascular disease: The impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. Pharmacotherapy 2002;22(6):738-47.
18. Clifford RM, Davis W, Batty K, Davis T. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes. Diabetes Care 2005;28:771-6.